Brief: Rezolute Receives Breakthrough Therapy Designation From FDA For Ersodetug In The Treatment Of Hypoglycemia Due To Congenital Hyperinsulinism

Rezolute

07/01/2025 13:08

Jan 7 (Reuters) - Rezolute Inc  RZLT.O :
    * REZOLUTE RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM
FDA FOR
ERSODETUG IN THE TREATMENT OF HYPOGLYCEMIA DUE TO CONGENITAL
HYPERINSULINISM
    * REZOLUTE INC: TOPLINE SUNRIZE DATA EXPECTED SECOND HALF OF
THIS
YEAR

Source text:  ID:nGNX45q53H 
Further company coverage:  RZLT.O 

 ((Reuters.Briefs@thomsonreuters.com;))